SmartNuclide Biopharma
China - ShanghaiPharmaceutical
Focus: SmartNuclide Biopharma is a Shanghai-based radiopharmaceutical company founded in 2015 specializing in molecular imaging and targeted therapy for oncology. The company operates as a pre-revenue biotech focused on early-stage radiopharmaceutical development.
Profile data last refreshed 17h ago · AI intelligence enriched 1w ago
Open Jobs
0
About SmartNuclide Biopharma
AI assessmentNot HiringNo open roles listed right now. Follow SmartNuclide Biopharma to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from SmartNuclide Biopharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
7 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
68Ga-NODAGA-SNA006
Solid TumorClinical Trials (2)
NCT05126927A PET Imaging Agent to Assess the Level of Tumor Tissue-infiltrating CD8 + T Cells in Patients With Solid Tumors
Phase 1Help build intelligence for SmartNuclide Biopharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.